Category I

Immune System Booster


Vitality Works, Inc
Human Otc Drug
NDC 64616-082
Category I also known as Immune System Booster is a human otc drug labeled by 'Vitality Works, Inc'. National Drug Code (NDC) number for Category I is 64616-082. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Category I drug includes Actaea Spicata Root - 6 [hp_X]/mL Anagallis Arvensis - 6 [hp_X]/mL Argemone Mexicana - 15 [hp_X]/mL Candida Albicans - 17 [hp_X]/mL Heloderma Horridum Venom - 14 [hp_X]/mL Hyoscyamus Niger - 5 [hp_X]/mL Potassium Dichromate - 10 [hp_X]/mL Potassium Iodide - 10 [hp_X]/mL Potassium Nitrate - 10 [hp_X]/mL Potassium Phosphate, Dibasic - 10 [hp_X]/mL and more. The currest status of Category I drug is Active.

Drug Information:

Drug NDC: 64616-082
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Category I
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Immune System Booster
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Vitality Works, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACTAEA SPICATA ROOT - 6 [hp_X]/mL
ANAGALLIS ARVENSIS - 6 [hp_X]/mL
ARGEMONE MEXICANA - 15 [hp_X]/mL
CANDIDA ALBICANS - 17 [hp_X]/mL
HELODERMA HORRIDUM VENOM - 14 [hp_X]/mL
HYOSCYAMUS NIGER - 5 [hp_X]/mL
POTASSIUM DICHROMATE - 10 [hp_X]/mL
POTASSIUM IODIDE - 10 [hp_X]/mL
POTASSIUM NITRATE - 10 [hp_X]/mL
POTASSIUM PHOSPHATE, DIBASIC - 10 [hp_X]/mL
SENNA LEAF - 7 [hp_X]/mL
SPONGIA OFFICINALIS SKELETON, ROASTED - 15 [hp_X]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 20 Mar, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 08 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Vitality Works, Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185372
N0000175629
N0000184306
N0000185001
M0008890
M0000728
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:3FU86L9OS0
46883LR90E
6X68976407
4D7G21HDBC
O9M1UQ4YIO
4WRK2153H3
T4423S18FM
1C4QK22F9J
RU45X2JN0Z
CI71S98N1Z
AK7JF626KX
1PIP394IID
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Fungal Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Increased IgG Production [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Fungal Proteins [CS]
Allergens [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Fungal Proteins [CS]
Increased Histamine Release [PE]
Increased IgG Production [PE]
Non-Standardized Fungal Allergenic Extract [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
64616-082-0259 mL in 1 BOTTLE, DROPPER (64616-082-02)16 Apr, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Category i temporarily eases malaise, flu and cold symptoms and aches.

Product Elements:

Category i immune system booster alcohol water actaea spicata root actaea spicata root anagallis arvensis anagallis arvensis argemone mexicana argemone mexicana candida albicans candida albicans heloderma horridum venom heloderma horridum venom hyoscyamus niger hyoscyamus niger potassium dichromate dichromate ion potassium iodide iodide ion potassium nitrate nitrate ion potassium phosphate, dibasic phosphate ion senna leaf senna leaf spongia officinalis skeleton, roasted spongia officinalis skeleton, roasted

Indications and Usage:

Category i for the temporary relief of general systemic malise, flu and cold symptoms and achiness.

Warnings:

Category i use only under the direction of a health care professional. do not use if tamper evident seal is broken or missing.

Dosage and Administration:

Category i orally 25 drops, 2 times per day or as indicated by a physician. children 12 and under use one half the adult.

Package Label Principal Display Panel:

Category i label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.